Stocks · News reference
Adlai Nortye Group enters Clinical Trial Collaboration And Supply Agreements With Eli Lilly And Merck KGaA For The ERBITUX Anti-EGFR Antibody
These agreements will support Adlai Nortye’s ongoing Phase I trial evaluating AN4035, a pan-RAS(ON) inhibitor-based ADC, both as monotherapy and in combination with cetuximab, in CEACAM5-enriched RAS-addicted solid
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Penske Automotive, OPKO Health, Ericsson And Other Big Stocks Moving Higher On Thursday
U.S. stocks mixed; Dow up ~200 points. Penske Automotive surged on a $16.3B go-private deal, while OPKO, Ericsson and others rallied.
Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab
Adlai Nortye announced clinical trial collaboration and supply agreements with Eli Lilly and Merck KGaA, Darmstadt, Germany to evaluate AN4035, a first-in-class pan-RAS(ON) inhibitor-based ADC, in combination with cetuximab in an ongoing global Phase I trial for CEACAM5-enriched RAS-addicted solid tumors. Both companies will supply cetuximab at no cost for their respective trial sites.
Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher
Eli Lilly's pipeline extends beyond its blockbuster weight-loss drug Zepbound, with three promising medicines poised to drive future growth: Foundayo (oral GLP-1 for weight loss), Onswik (once-weekly basal insulin for diabetes), and retatrutide (investigational triple-hormone weight-loss drug showing 28.3% average weight loss). These drugs target different patient segments and indications, positioning Eli Lilly to maintain market leadership despite increasing competition.
Novo Nordisk and Eli Lilly Just Got Some Fantastic News
A NIH-funded study found that the GLP-1 drug semaglutide extended lifespan and slowed aging in older mice by improving muscle and cognitive function and reducing inflammation. The findings could accelerate adoption of GLP-1 drugs from Novo Nordisk and Eli Lilly, with forecasts predicting 25 million Americans on these treatments by 2030 and a market reaching $190 billion by 2035.
Eli Lilly's GLP-1 Pill Wins Key European Backing for Obesity and Diabetes
Eli Lilly gains positive CHMP opinion for Foundayo (orforglipron), a new oral GLP-1 tablet for weight loss and type 2 diabetes.